Contact
searchSearch
HMP Global
Quiz

Progression from PsO to PsA

Rebecca Mashaw
04/28/2026

Related Content

Philip Mease
Expert Insights
Philip Mease, MD, on the POETYK Trials of Deucravacitinib in PsA
04/23/2026
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 1 of a two-part podcast,...
04/23/2026
Rheumatology & Arthritis
Alexis Ogdie
Expert Insights
Alexis Ogdie, MD, on Obesity in Psoriatic Arthritis and GLP-1s: Part 2
04/16/2026
Alexis Ogdie, MD
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In part 2 of her video on psoriatic arthritis and obesity, Dr Ogdie reviews recent studies showing how combination therapy with GLP-1 RAs may not only boost weight loss but also help patients achieve minimal disease activity.
In part 2 of her video on...
04/16/2026
Rheumatology & Arthritis
Alexis Ogdie
Expert Insights
Alexis Ogdie, MD, on the Impact of Obesity in Psoriatic Arthritis: Part 1
04/16/2026
Alexis Ogdie, MD
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
In the first of two videos on the impact and treatment of obesity in psoriatic arthritis, Dr Alexis Ogdie reviews recent research on how obesity affects the severity of disease and the effect of weight loss on patients with PsA.
In the first of two videos on...
04/16/2026
Rheumatology & Arthritis
Laura Coates
Expert Insights
Laura Coates, MBChB, on Progression to Psoriatic Arthritis from Psoriasis
04/16/2026
Laura Coates, MBChB
Dr Coates discusses a post-hoc analysis of the FOREMOST study that aimed to identify psoriatic arthritis patients at the highest risk of progressing from fewer than 5 tender or swollen joints to polyarticular disease with much higher counts...
Dr Coates discusses a post-hoc analysis of the FOREMOST study that aimed to identify psoriatic arthritis patients at the highest risk of progressing from fewer than 5 tender or swollen joints to polyarticular disease with much higher counts...
Dr Coates discusses a post-hoc...
04/16/2026
Rheumatology & Arthritis

Popular Articles

Sponsored Video
The RheuMuseum Lecture Series: The Pathogenesis of Psoriatic Arthritis
06/04/2024
The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.
The RheuMuseum Lecture Series continues with Professor Iain McInnes taking a deeper dive into the pathogenesis of psoriatic arthritis.
The RheuMuseum Lecture Series...
06/04/2024
Rheumatology & Arthritis
FDA Alert
FDA Approves Bimekizumab for PsA, nr-axSpA and AS
09/23/2024
Rebecca Mashaw
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
Already approved for plaque...
09/23/2024
Rheumatology & Arthritis
News
Predictors of Demyelinating Disease in axSpA
07/11/2024
Jessica Garlewicz
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating disease development included a diagnosis of axial spondyloarthritis, presence of inflammatory bowel disease, and a history of smoking.
Key predictors of demyelinating...
07/11/2024
Rheumatology & Arthritis
News
No Major Risk of CVD Events With JAKs or bDMARDs in RA
08/23/2024
Jessica Garlewicz
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no...
08/23/2024
Rheumatology & Arthritis
News
Relations Between Clinical Response Criteria and Disease Activity Levels With Axial Spondyloarthritis
05/14/2024
Jessica Garlewicz
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
Researchers aimed to evaluate how achieving different levels of clinical response or disease activity in patients with nonradiographic (nr-) and radiographic (r-) axial spondyloarthritis.
Researchers aimed to evaluate...
05/14/2024
Rheumatology & Arthritis

Partner Spotlight

Axial Involvement in SpA: A Patient-Centered Exploration, Chapter 1
SPONSORED
Axial Involvement in SpA, Chapter 1
04/26/2022
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA.
Ethan Craig, MD, MPH, discusses...
04/26/2022
Rheumatology & Arthritis

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use